Verinata Health, (Verinata), a wholly-owned subsidiary of Illumina, Inc., is driven by a sole and extraordinary purpose — maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities through our proprietary technologies.
We support national guidelines issued by the American Congress of Obstetrics and Gynecology (ACOG) recommending all women be offered prenatal screening and diagnosis for fetal aneuploidy, and additionally the ACOG committee opinion stating that cell-free DNA testing can be an option for high risk pregnant women. We believe women who desire a safe and accurate assessment of fetal aneuploidy should be offered a noninvasive blood test that yields clear results.
By offering the verifi® prenatal test, we aim to greatly improve the accuracy and safety associated with today’s multi-step screening and diagnostic process for fetal genetic disorders. The verifi® test is a noninvasive prenatal test that analyzes cell-free DNA in maternal blood to detect trisomy 21 (Down syndrome), trisomy 18, trisomy 13 and sex chromosome aneuploidies as early as 10 weeks gestation. The verifi® test is available for pregnant women with singleton gestations determined to be at high risk by their physician.
Verinata Health is excited to be at the forefront of improving prenatal testing options for pregnant women. Founded with strong academic and scientific support from major medical and clinical research institutes, the company is committed to helping clinicians offer the latest in prenatal care to patients.